Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Faraj

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Antimicrobial Agents and Chemotherapy|March 4, 2020
Drug Effect of Clofazimine on Persisters Explains an Unexpected Increase in Bacterial Load in PatientsAlan Faraj, Robin J Svensson, Andreas H Diacon, et al.
Clinical Pharmacology and Therapeutics|January 4, 2024
Subcutaneous Marzeptacog Alfa (Activated) for On-Demand Treatment of Bleeding Events in Subjects With Hemophilia A or B With InhibitorsAlan Faraj, Joakim Nyberg, Grant E Blouse, et al.
Journal of Pharmacokinetics and Pharmacodynamics|June 4, 2020
A model-based analysis identifies differences in phenotypic resistance between in vitro and in vivo: implications for translational medicine within tuberculosisOskar Clewe, Alan Faraj, Yanmin Hu, et al.
CPT: Pharmacometrics & Systems Pharmacology|October 3, 2022
Phase III dose selection of marzeptacog alfa (activated) informed by population pharmacokinetic modeling: A novel hemostatic drugAlan Faraj, Tom Knudsen, Shraddha Desai, et al.
Advances in Therapy|June 21, 2023
Model-Informed Support of Dose Selection for Prophylactic Treatment with Dalcinonacog Alfa in Adult and Paediatric Hemophilia B PatientsAlan Faraj, Natacha Le Moan, Eduard Gorina, et al.
Scientific Reports|September 24, 2020
Difference in persistent tuberculosis bacteria between in vitro and sputum from patients: implications for translational predictionsAlan Faraj, Oskar Clewe, Robin J Svensson, et al.
CPT: Pharmacometrics & Systems Pharmacology|April 12, 2023
Model-informed pediatric dose selection of marzeptacog alfa (activated): An exposure matching strategyAlan Faraj, Rob C van Wijk, Linda Neuman, et al.
Frontiers in Pharmacology|May 1, 2023
Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug developmentLaurynas Mockeliunas, Alan Faraj, Rob C van Wijk, et al.
Plos Biology|August 19, 2024
A noninvasive BCG skin challenge model for assessing tuberculosis vaccine efficacyNitya Krishnan, Miles Priestman, Iria Uhía, et al.
American Journal of Respiratory and Critical Care Medicine|March 8, 2022
Early Bactericidal Activity of Meropenem plus Clavulanate (with or without Rifampin) for Tuberculosis: The COMRADE Randomized, Phase 2A Clinical TrialVeronique De Jager, Nikhil Gupte, Silvia Nunes, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Antimicrobial Agents and Chemotherapy|March 4, 2020
Drug Effect of Clofazimine on Persisters Explains an Unexpected Increase in Bacterial Load in PatientsAlan Faraj, Robin J Svensson, Andreas H Diacon, et al.
Clinical Pharmacology and Therapeutics|January 4, 2024
Subcutaneous Marzeptacog Alfa (Activated) for On-Demand Treatment of Bleeding Events in Subjects With Hemophilia A or B With InhibitorsAlan Faraj, Joakim Nyberg, Grant E Blouse, et al.
Journal of Pharmacokinetics and Pharmacodynamics|June 4, 2020
A model-based analysis identifies differences in phenotypic resistance between in vitro and in vivo: implications for translational medicine within tuberculosisOskar Clewe, Alan Faraj, Yanmin Hu, et al.
CPT: Pharmacometrics & Systems Pharmacology|October 3, 2022
Phase III dose selection of marzeptacog alfa (activated) informed by population pharmacokinetic modeling: A novel hemostatic drugAlan Faraj, Tom Knudsen, Shraddha Desai, et al.
Advances in Therapy|June 21, 2023
Model-Informed Support of Dose Selection for Prophylactic Treatment with Dalcinonacog Alfa in Adult and Paediatric Hemophilia B PatientsAlan Faraj, Natacha Le Moan, Eduard Gorina, et al.
Scientific Reports|September 24, 2020
Difference in persistent tuberculosis bacteria between in vitro and sputum from patients: implications for translational predictionsAlan Faraj, Oskar Clewe, Robin J Svensson, et al.
CPT: Pharmacometrics & Systems Pharmacology|April 12, 2023
Model-informed pediatric dose selection of marzeptacog alfa (activated): An exposure matching strategyAlan Faraj, Rob C van Wijk, Linda Neuman, et al.
Frontiers in Pharmacology|May 1, 2023
Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug developmentLaurynas Mockeliunas, Alan Faraj, Rob C van Wijk, et al.
Plos Biology|August 19, 2024
A noninvasive BCG skin challenge model for assessing tuberculosis vaccine efficacyNitya Krishnan, Miles Priestman, Iria Uhía, et al.
American Journal of Respiratory and Critical Care Medicine|March 8, 2022
Early Bactericidal Activity of Meropenem plus Clavulanate (with or without Rifampin) for Tuberculosis: The COMRADE Randomized, Phase 2A Clinical TrialVeronique De Jager, Nikhil Gupte, Silvia Nunes, et al.
Pageof 1